Anika Therapeutics, Inc. (ANIK) Stands out Over Competition

In 2010, the company’s revenue doubled to $60 million, before falling the next year to $15 million, and then more than doubling again to $33 million. And that wild swing may not be for everyone especially since the firm lost $15 million in 2011. Still, the company is solidifying its balance sheet and is entering the presentation arena, which can increase exposure, and particularly investment value. But right now, an investment in Immunomedics, Inc. (NASDAQ:IMMU) is based purely on speculation.

Breaking it all down

Anika Therapeutics, Inc. (NASDAQ:ANIK) Therapeutics has been able to earn an attractive profit margin because of the type of healing the company does. The hydraulic acid the firm uses is relatively cheap to manufacture. And because the firm has a lock on the process, it doesn’t need to dedicate more money than it can handle to research and development, which is the source of massive expenses for most of its peers. This sets Anika Therapeutics, Inc. (NASDAQ:ANIK) apart as a solid biotech with minimal uncertainty.

Phillip Woolgar owns shares of Anika Therapeutics. The Motley Fool has no position in any of the stocks mentioned. Phillip is a member of The Motley Fool Blog Network — entries represent the personal opinion of the blogger and are not formally edited.

The article Anika Stands out Over Competition originally appeared on Fool.com is written by Phillip Woolgar.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.